web analytics

Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has been enrolled in the ongoing phase III study using calcipotriol spray against mild to moderate psoriasis. Results from the study are expected to be presented in December 2019.
Lipidor has developed a sprayable calcipotriol product, Calcipotriol/AKVANO 50 µg/g cutaneous solution (AKP01), formulated with the company’s lipid-based technology, providing more precise dosing and increased comfort to patients.

 “We are pleased to see that the study follows the time plan and that all patients now are included,” says Lipidor CEO Ola

Source: Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.